Protara Therapeutics, Inc. (TARA) has a negative trailing P/E of -4.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 59.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -24.13%, forward earnings yield 1.69%. PEG 0.05 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.1 | -0.03 | 0.82 | 0.00 | - |
| 2017 | -1.1 | -1.57 | 0.94 | 0.00 | - |
| 2018 | -9.1 | 0.11 | 11.37 | 0.00 | - |
| 2019 | -4.4 | 0.07 | 10.42 | 0.00 | - |
| 2020 | -5.2 | -0.17 | 0.88 | 0.00 | - |
| 2021 | -1.6 | 0.15 | 0.47 | 0.00 | - |
| 2022 | -0.5 | -0.01 | 0.30 | 0.00 | - |
| 2023 | -0.5 | 0.01 | 0.31 | 0.00 | - |
| 2024 | -2.4 | 0.06 | 0.65 | 0.00 | - |
| 2025 | -4.0 | 0.10 | 1.16 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-68.90 | $0.00 | $-28.53M | - |
| 2017 | $-69.38 | $0.00 | $-29.96M | - |
| 2018 | $-9.93 | $0.00 | $-25.44M | - |
| 2019 | $-228.60 | $0.00 | $-14.73M | - |
| 2020 | $-4.63 | $0.00 | $-33.51M | - |
| 2021 | $-4.20 | $0.00 | $-47.14M | - |
| 2022 | $-5.76 | $0.00 | $-64.82M | - |
| 2023 | $-3.57 | $0.00 | $-40.42M | - |
| 2024 | $-2.17 | $0.00 | $-44.6M | - |
| 2025 | $-1.34 | $0.00 | $-57.44M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.51 | $-1.77 – $-1.25 | $22.3M | $22.3M – $22.3M | 6 |
| 2027 | $-1.56 | $-1.80 – $-1.12 | $25.33M | $25.33M – $25.33M | 5 |
| 2028 | $-0.86 | $-1.29 – $-0.18 | $119.75M | $119.75M – $119.75M | 4 |
| 2029 | $0.09 | $0.09 – $0.09 | $240.42M | $240.42M – $240.42M | 2 |
| 2030 | $1.03 | $1.03 – $1.03 | $328.01M | $328.01M – $328.01M | 2 |
